{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:25:40Z","timestamp":1793953540955,"version":"4.8.0"},"reference-count":139,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.cpcardiol.2023.101596","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T15:13:17Z","timestamp":1674054797000},"page":"101596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Management of Heart Failure With Reduced Ejection Fraction"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6394-1540","authenticated-orcid":false,"given":"Ahmed Mustafa","family":"Rashid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Fudim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy A.","family":"DeWald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"DeVore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13S","key":"10.1016\/j.cpcardiol.2023.101596_bib0001","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/S0735-1097(16)31411-5","article-title":"Using technology to reduce readmission rates for congestive heart failure in high risk patients","volume":"67","author":"Vadlamani","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0002","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2013.11.053","article-title":"The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries","volume":"63","author":"Ambrosy","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0003","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics\u20142018 update: a report from the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0004","doi-asserted-by":"crossref","first-page":"e1932","DOI":"10.7205\/MILMED-D-17-00017","article-title":"Repeat hospitalizations predict mortality in patients with heart failure","volume":"182","author":"Lin","year":"2017","journal-title":"Mil Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0005","doi-asserted-by":"crossref","first-page":"e59225","DOI":"10.1371\/journal.pone.0059225","article-title":"Prevalence of symptomatic heart failure with reduced and with normal ejection fraction in an elderly general population-the CARLA study","volume":"8","author":"Tiller","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0006","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","article-title":"Epidemiology and aetiology of heart failure","volume":"13","author":"Ziaeian","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0007","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0008","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2010.165","article-title":"Epidemiology and risk profile of heart failure","volume":"8","author":"Bui","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0009","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ehf2.12005","article-title":"Heart failure: preventing disease and death worldwide","volume":"1","author":"Ponikowski","year":"2014","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0010","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012199","article-title":"Regional variation of mortality in heart failure with reduced and preserved ejection fraction across Asia: outcomes in the ASIAN-HF registry","volume":"9","author":"MacDonald","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0011","series-title":"Heart disease","first-page":"493","article-title":"Clinical manifestations of heart failure","author":"Braunwald","year":"1980"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0012","first-page":"531","article-title":"CCS\/CHFS Heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction","volume":"37","author":"McDonald","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0013","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0014","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2021.05.002","article-title":"Kidney function and outcomes in patients hospitalized with heart failure","volume":"78","author":"Patel","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0016","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0017","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0018","first-page":"469","article-title":"Contemporary treatment patterns and clinical outcomes of comorbid diabetes mellitus and HFrEF: the CHAMP-HF registry","volume":"8","author":"Vaduganathan","year":"2020","journal-title":"Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0019","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0020","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/ejhf.900","article-title":"Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF","volume":"19","author":"Ferreira","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0021","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jacc.2021.06.040","article-title":"Device therapy in chronic heart failure: JACC state-of-the-art review","volume":"78","author":"Fudim","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0022","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0023","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro\u2013B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0024","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin\u2013neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0025","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","article-title":"Efficacy of \u03b2 blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis","volume":"384","author":"Kotecha","year":"2014","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0026","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/01.CIR.90.4.1765","article-title":"Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS)","volume":"90","author":"Investigators","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0027","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0028","first-page":"2001","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in-congestive heart failure (MERIT-HF)","volume":"353","author":"Group","year":"1999","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0029","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0030","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/CIRCULATIONAHA.109.895235","article-title":"Aldosterone receptor antagonists: effective but often forgotten","volume":"121","author":"Maron","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0031","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0032","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0033","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0034","doi-asserted-by":"crossref","first-page":"e009429","DOI":"10.1161\/JAHA.118.009429","article-title":"Hyperkalemia in heart failure: probably not O\"K\"","volume":"7","author":"Fudim","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0035","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/jama.2020.10262","article-title":"Heart failure with reduced ejection fraction: a review","volume":"324","author":"Murphy","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0036","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0037","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0038","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0039","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0040","series-title":"Farxiga phase III DAPA-CKD trial will be stopped early after overwhelming efficacy in patients with chronic kidney disease","year":"2020"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0041","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0042","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/ijem.IJEM_244_18","article-title":"High prevalence of genital mycotic infections with sodium-glucose co-transporter 2 inhibitors among indian patients with type 2 diabetes","volume":"23","author":"Aggarwal","year":"2019","journal-title":"Ind J Endocrinol Metabol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0043","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0044","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1093\/eurheartj\/ehac293","article-title":"Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial","volume":"43","author":"Metra","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/jamacardio.2021.4027","article-title":"Assessment of Omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial","volume":"7","author":"Felker","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0046","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/ehf2.12797","article-title":"Anaemia, iron deficiency and heart failure in 2020: facts and numbers","volume":"7","author":"Chopra","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0047","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0048","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0049","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ehf2.12250","article-title":"Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF)","volume":"5","author":"Yeo","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0050","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1001\/jama.2017.5427","article-title":"Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial","volume":"317","author":"Lewis","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0051","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00002018-200831020-00001","article-title":"If inhibition with ivabradine","volume":"31","author":"Savelieva","year":"2008","journal-title":"Drug Saf"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0052","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0053","unstructured":"Bemme S, Weick M, Gollisch T. Effect of ivabradine on the activity of retinal ganglion cells."},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0054","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0055","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0056","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0057","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0058","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1161\/CIRCULATIONAHA.110.960898","article-title":"Effectiveness of cardiac resynchronization therapy by QRS morphology in the multicenter automatic defibrillator implantation trial\u2013cardiac resynchronization therapy (MADIT-CRT)","volume":"123","author":"Zareba","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0059","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1306687","article-title":"Cardiac-resynchronization therapy in heart failure with a narrow QRS complex","volume":"369","author":"Ruschitzka","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0060","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0061","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa033088","article-title":"Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy","volume":"350","author":"Kadish","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0062","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter\u2013defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0063","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","author":"K\u00f8ber","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0064","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter mitral-valve repair in patients with heart failure","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0065","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","article-title":"Percutaneous repair or medical treatment for secondary mitral regurgitation","volume":"379","author":"Obadia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0066","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jamacardio.2019.5971","article-title":"New evidence supporting a novel conceptual framework for distinguishing proportionate and disproportionate functional mitral regurgitation","volume":"5","author":"Packer","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0067","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/jamacardio.2019.5980","article-title":"An appraisal of the association of clinical outcomes with the severity of regurgitant volume relative to end-diastolic volume in patients with secondary mitral regurgitation","volume":"5","author":"Gaasch","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0068","first-page":"945","article-title":"The REDUCE FMR trial: a randomized sham-controlled study of percutaneous mitral annuloplasty in functional mitral regurgitation","volume":"7","author":"Witte","year":"2019","journal-title":"JACC: Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0069","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/ehf2.13301","article-title":"Effect of Carillon Mitral Contour System on patient-reported outcomes in functional mitral regurgitation: an individual participant data meta-analysis","volume":"8","author":"Khan","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0070","first-page":"874","article-title":"A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation","volume":"6","author":"Abraham","year":"2018","journal-title":"JACC: Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0071","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.CIR.69.3.451","article-title":"Selective impairment of baroreflex-mediated vasoconstrictor responses in patients with ventricular dysfunction","volume":"69","author":"Ferguson","year":"1984","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0072","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jash.2012.04.004","article-title":"Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial","volume":"6","author":"Hoppe","year":"2012","journal-title":"J Am Society Hypertension"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0073","first-page":"487","article-title":"Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction","volume":"3","author":"Abraham","year":"2015","journal-title":"JACC: Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0074","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacc.2012.03.023","article-title":"Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: a controlled trial investigating outcomes of exercise training) trial","volume":"60","author":"Fiuzat","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0075","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure","volume":"94","author":"Bristow","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0076","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0077","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0078","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0079","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1161\/CIRCULATIONAHA.118.039331","article-title":"Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril\/valsartan or enalapril in the PIONEER-HF trial","volume":"139","author":"Morrow","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0080","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0081","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/heartjnl-2018-314158","article-title":"Change in renal function associated with drug treatment in heart failure: national guidance","volume":"105","author":"Clark","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0082","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacc.2017.11.025","volume":"71","author":"Yancy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0083","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jacc.2003.12.040","article-title":"Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial","volume":"43","author":"Gattis","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0084","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0085","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1161\/01.CIR.80.3.551","article-title":"Long-term beta-blockade in dilated cardiomyopathy. Effects of short-and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol","volume":"80","author":"Waagstein","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0086","first-page":"647","article-title":"Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis","volume":"3","author":"Prins","year":"2015","journal-title":"JACC: Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0087","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.jacc.2003.11.037","article-title":"Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study","volume":"43","author":"Rouleau","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0088","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-019-1175-3","article-title":"Mineralocorticoid receptor antagonist use after hospitalization of patients with heart failure and post-discharge outcomes: a single-center retrospective cohort study","volume":"19","author":"Durstenfeld","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0089","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015042","article-title":"Real-world analysis of guideline-based therapy after hospitalization for heart failure","volume":"9","author":"Wirtz","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0090","series-title":"American College of Cardiology Foundation Washington DC","first-page":"1408","article-title":"Quadruple medical therapy for heart failure: medications working together to provide the best care","author":"Greene","year":"2021"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0091","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10741-018-9689-9","article-title":"Is there a blood pressure lowering effect of MRAs in heart failure? An overview and meta-analysis","volume":"23","author":"Bazoukis","year":"2018","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0092","first-page":"188","article-title":"Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction","volume":"8","author":"Serenelli","year":"2020","journal-title":"Heart Failure"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0093","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0094","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0095","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jacbts.2021.10.018","article-title":"Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care?","volume":"7","author":"Sharma","year":"2022","journal-title":"Basic to Translational Science"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0096","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0097","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0098","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006623","article-title":"Practical considerations for the use of sodium-glucose co-transporter 2 inhibitors in heart failure","volume":"13","author":"Honigberg","year":"2020","journal-title":"Circulat Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0099","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.121.058910","article-title":"Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: Insights from DAPA-HF","volume":"146","author":"Adamson","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0100","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIRCULATIONAHA.120.052926","article-title":"How should we sequence the treatments for heart failure and a reduced ejection fraction? A redefinition of evidence-based medicine","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0101","first-page":"632","article-title":"A novel approach to medical management of heart failure with reduced ejection fraction","volume":"37","author":"Miller","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0102","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamacardio.2021.0496","article-title":"Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure\u2014optimizing therapy with the need for speed","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0103","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ejhf.1474","article-title":"Novel potassium binders as enabling therapy in heart failure","volume":"21","author":"Butler","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0104","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/ejhf.2259","article-title":"Effect of sacubitril\/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial","volume":"23","author":"Bhatt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0105","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0106","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1002\/clc.23846","article-title":"Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction","volume":"45","author":"Talha","year":"2022","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0107","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","article-title":"Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials","volume":"110","author":"Young","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0108","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0109","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0110","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0111","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0112","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0113","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ehf2.12528","article-title":"Eligibility of sodium\u2013glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure","volume":"7","author":"Sharma","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0114","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ejhf.1351","article-title":"Medication dosing for heart failure with reduced ejection fraction\u2014opportunities and challenges","volume":"21","author":"Marti","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0115","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? evidence from 12 440 patients of the ESC heart failure long-term registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0116","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/ejhf.580","article-title":"Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial","volume":"18","author":"Vardeny","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0117","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0118","doi-asserted-by":"crossref","DOI":"10.1161\/xJAHA.111.000018","article-title":"Incremental reduction in risk of death associated with use of guideline-recommended therapies in patients with heart failure: a nested case-control analysis of IMPROVE HF","volume":"1","author":"Fonarow","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0119","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/ejhf.2149","article-title":"Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction","volume":"23","author":"Packer","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0120","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ejhf.1645","article-title":"European society of cardiology heart failure long-term registry investigators group. sex-and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP heart failure long-term registry","volume":"22","author":"Lain\u0161\u010dak","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0121","first-page":"725","article-title":"Care gaps in adherence to heart failure guidelines: clinical inertia or physiological limitations?","volume":"8","author":"Jarjour","year":"2020","journal-title":"Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0122","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ejhf.1459","article-title":"Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry","volume":"21","author":"Komajda","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0123","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.amjmed.2021.03.038","article-title":"Polypharmacy in heart failure with reduced ejection fraction: progress, not problem","volume":"134","author":"Rao","year":"2021","journal-title":"Am J Med"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0124","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1177\/2047487319835042","article-title":"Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction","volume":"26","author":"Veenis","year":"2019","journal-title":"Eur J Prevent Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0125","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0126","doi-asserted-by":"crossref","first-page":"f521","DOI":"10.1136\/bmj.f521","article-title":"Income inequality and 30 day outcomes after acute myocardial infarction, heart failure, and pneumonia: retrospective cohort study","volume":"346","author":"Lindenauer","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0127","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/ejhf.2143","article-title":"The heart failure association atlas: heart failure epidemiology and management statistics 2019","volume":"23","author":"Seferovi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0128","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013459","article-title":"Improving care for heart failure patients in primary care, GPs' perceptions: a qualitative evidence synthesis","volume":"6","author":"Smeets","year":"2016","journal-title":"BMJ open"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0129","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/j.jacc.2003.12.043","article-title":"From knowledge to practice in chronic cardiovascular disease: a long and winding road","volume":"43","author":"Majumdar","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0130","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s10741-020-09979-z","article-title":"Clinical inertia in the treatment of heart failure: a major issue to tackle","volume":"26","author":"Verhestraeten","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0131","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/ejhf.2378","article-title":"Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction","volume":"23","author":"Seferovi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0132","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cjco.2020.05.009","article-title":"Cost-effectiveness of earlier transition to angiotensin receptor neprilysin inhibitor in patients with heart failure and reduced ejection fraction","volume":"2","author":"Grant","year":"2020","journal-title":"CJC Open"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0133","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1111\/dom.14162","article-title":"Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence","volume":"22","author":"McEwan","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0134","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/heartjnl-2016-310661","article-title":"Cost-effectiveness of sacubitril\/valsartan in the treatment of heart failure with reduced ejection fraction","volume":"104","author":"McMurray","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0135","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002606","article-title":"Medication adherence interventions improve heart failure mortality and readmission rates: systematic review and meta-analysis of controlled trials","volume":"5","author":"Ruppar","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0136","doi-asserted-by":"crossref","first-page":"e10057","DOI":"10.2196\/10057","article-title":"Mobile phone apps to support heart failure self-care management: integrative review","volume":"2","author":"Athilingam","year":"2018","journal-title":"JMIR Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0137","article-title":"Disease management interventions for heart failure","volume":"1","author":"Takeda","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0138","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/ejhf.765","article-title":"Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis","volume":"19","author":"Van Spall","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101596_bib0139","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/ehjcvp\/pvaa085","article-title":"Pragmatic approaches to the next generation of clinical trials in heart failure","volume":"6","author":"Lund","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623000130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623000130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:07:47Z","timestamp":1758938867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280623000130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":139,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0146280623000130"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101596","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Heart Failure With Reduced Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101596","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101596"}}